Proposed US legislation that would shift the landscape for 180-day exclusivity for generic first filers challenging originator patents has once again come under attack from the US Association for Accessible Medicines, which has labelled it “overly broad,” and “well-intended but misguided,” ultimately with the potential to weaken the primary incentives for generics manufacturers.
Primarily, the off-patent industry association targets the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act, otherwise...
